Context：Polycystic ovary syndrome (PCOS) is one of the most common endocrine and metabolic disorders, affecting 6% -15% women of reproductive age. Objective: The study aims to investigate the clinical predictive value of anti-Mullerian hormone (AMH) and various endocrine indicators in patients with and without polycystic ovary syndrome (PCOS). Patient(s): A total of 636 PCOS patients (study group) and 94 non-PCOS patients (control group) were enrolled. Intervention(s): None Main Outcome Measure(s): Fasting blood samples and anthropometric parameters were collected. Endocrine hormones such as anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) and testosterone (T) were measured. Result(s): The concentration of AMH, LH, T and BMI in PCOS group were significantly higher than in control group (p < 0.05). FSH/LH ratio was significantly lower than that in control group (p < 0.05). The FSH level in study group was lower than that in control group but without statistical difference (p > 0.05). ROC curve analysis of serum AMH and other indicators in prediction of PCOS showed that serum AMH obtained the largest area under the ROC curve (AUC). The area under the curve of serum AMH was the 0.806, with a cut-off value of 4.84 μg/L. The sensitivity and specificity were 84.2% and 64.9%, respectively. Conclusions: The AMH has the best predictive value of PCOS among these indicators. Patients whose AMH level exceed 4.84 μg/L might be associated with the risk of PCOS.